Dr. Moein Moghimi

Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine at the School of Pharmacy, and Translational and Clinical Research Institute, Newcastle University (UK), and an Adjoint Professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver. He is also co-founder of three spin-offs in USA and UK, and Associate Editor of Molecular Therapy (Cell Press). He graduated with Honors in Biochemistry from the University of Manchester (UK) in 1985 and then completed a PhD in Biochemistry at Charing Cross and Westminster Medical School (Imperial College, London).

Moghimi is widely recognised for his contribution to fundamental and translational research in nanomedicine and drug delivery, especially in mechanistic understanding of nanoparticle-mediated complement activation and infusion reactions, and as an inventor of many nanosystems for tissue-specific targeting. The latter have included “splenotropic” and “lymphotropic” nanoparticles. Among the latest inventions of Moghimi’s laboratory are the NanoLigand Carriers. These are induced self-assemblies of phage-derived display peptides that on intravenous injection rapidly target two receptors on the blood brain-barrier, reaching neurons and microglia. A 2021 study by Stanford University list Moghimi among the top 0.08% of world’s leading scientists across in all fields, and rank him at 53 (out of 131,063) in the field of pharmacology in the world and 28 in Europe. As to date, Moghimi’s research programme has secured over €25 million funding. He is widely published (>300 research papers, reviews, book chapters, proceedings, etc., ORCID: 0000-0003-0836-926X) and cited (>24,000 citations and h-index of 70, GS as of Jan 2022), and has delivered >400 invited plenaries, keynote speeches and distinguished lectures world-wide. He also serves on editorial board of >10 international journals including Advanced Drug Delivery Reviews, Journal of Controlled Release and Nanomedicine (Lond.). He is also an active consultant to industry and governmental organisations.